Physician profile
Asim Ulusarac
NPI 1730151671
$11,995.31
in general payments reported to CMS, 2019-2025
33 companies · $2,851 in 2025
The $2,851 reported for 2025 was more than what 92% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,180 · 2020: $966 · 2021: $1,087 · 2022: $1,022 · 2023: $2,366 · 2024: $2,523 · 2025: $2,851.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,735 · Education: $5.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,735.36 |
| Education | $5.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,306.71 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $1,465.47 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $895.24 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Janssen Pharmaceuticals, INC | $869.73 | 2019-2025 | Spravato, Invega Sustenna |
| Sunovion Pharmaceuticals INC. | $754.59 | 2019-2022 | |
| Tris Pharma INC | $570.51 | 2019-2025 | Dyanavel Xr |
| Lundbeck LLC | $482.81 | 2019-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $467.67 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $465.12 | 2022-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $385.19 | 2022-2025 | Qelbree, Qelbree |
| Allergan, INC. | $379.43 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $360.82 | 2019-2025 | Fanapt, Hetlioz |
| Corium, LLC | $338.00 | 2021-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $333.62 | 2019-2025 | Trintellix |
| Alkermes, INC. | $304.46 | 2019-2025 | Aristada, Lybalvi |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $229.47 | 2021-2025 | Xelstrym |
| Axsome Therapeutics, INC. | $198.67 | 2023-2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $196.23 | 2019-2024 | Jornay Pm |
| Bausch Health US, LLC | $143.09 | 2022-2025 | Aplenzin, Wellbutrin |
| Neos Therapeutics, LP | $120.34 | 2019-2023 | Adzenys Xr-Odt |
| Brainsway USA INC | $107.89 | 2025 | Deep Tms System |
| Vertical Pharmaceuticals, LLC | $101.62 | 2019-2025 | Relexxii |
| Jazz Pharmaceuticals INC. | $98.48 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $88.47 | 2024-2025 | Cobenfy |
| Shire North American Group INC | $74.20 | 2019 | |
| Collegium Pharmaceutical, INC. | $68.85 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $58.01 | 2023-2024 | Quviviq |
| Arbor Pharmaceuticals, INC. | $30.05 | 2019-2022 | |
| Almatica Pharma LLC | $25.82 | 2023-2024 | Loreev Xr |
| Merck Sharp & Dohme LLC | $19.61 | 2022 | |
| Biogen, INC. | $19.55 | 2024 | |
| Indivior INC. | $18.17 | 2023 | Perseris |
| Avanir Pharmaceuticals, INC. | $17.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asim Ulusarac listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.